Rhythm Biosciences
Rhythm's lead product, ColoSTAT, is intended to provide the accurate and early detection of colorectal cancer, acting as either a first-step screening test or within the triage of persons with a positive faecal immunochemical test (FIT) or.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | AUD1.0m | Post IPO Debt | |
| Total Funding | 000k | ||
| AUD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | (90 %) | 900 % | 100 % | 50 % | (44 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (262 %) | (3874 %) | (647 %) | (557 %) | (378 %) | (213 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (255 %) | (4023 %) | (661 %) | (440 %) | (274 %) | (406 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 1939 % | 455 % | 258 % | 122 % | 139 % |
Source: Company filings or news article
Related Content
Rhythm Biosciences is an innovative Australian, publicly listed medical diagnostics company specializing in the development of simple and affordable blood tests for the accurate detection of cancers. The company's flagship product, ColoSTAT, is a proprietary immunoassay designed for the early detection of colorectal cancer. Rhythm Biosciences aims to provide physicians with reliable diagnostic tools that can improve patient outcomes and reduce healthcare costs. The company primarily serves healthcare providers and operates within the medical diagnostics market. Its business model revolves around the commercialization of its diagnostic tests, generating revenue through product sales and potential licensing agreements. Additionally, Rhythm Biosciences is exploring the feasibility of applying its technology to detect other types of cancers, which could expand its market reach and revenue streams.
Keywords: Colorectal cancer, blood test, immunoassay, diagnostics, healthcare, physicians, affordable, early detection, medical technology, Australia.